Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : Increase of profitability guidance for financial year 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 09:59am EST

Hamburg - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) today announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company's financial performance.

Based on the preliminary unaudited consolidated results for the financial year 2019, the Company now expects an increase of the adjusted Group EBITDA by more than 25% (previously: improve by approx. 15%) for 2019 compared to previous year (2018: EUR 92.0 m). The positive adjustment of the guidance is primarily due to a strong operating performance in the fourth quarter of 2019 and unexpectedly high milestone revenues from long-term partnerships such as those with Celgene, Bayer and Sanofi in December 2019, which in particular needed to be clarified in terms of revenue recognition and the corresponding allocation to the 2019 or 2020 financial year.

All other elements of the Company's financial guidance are confirmed.

Contact:

Dr Werner Lanthaler

Tel: +49 (0)40.560 81-242

Email: werner.lanthaler@evotec.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EVOTEC SE
02/21EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
02/13EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/11EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/07EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/05EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
02/03EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
01/31EVOTEC : and Bayer advance further programme into Phase I clinical development
AQ
01/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
01/30EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
01/30EVOTEC : And bayer advance further programme into phase i clinical development
EQ
More news
Financials (EUR)
Sales 2019 429 M
EBIT 2019 59,5 M
Net income 2019 36,1 M
Finance 2019 5,50 M
Yield 2019 -
P/E ratio 2019 97,5x
P/E ratio 2020 70,9x
EV / Sales2019 8,22x
EV / Sales2020 7,25x
Capitalization 3 533 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 29,63  €
Last Close Price 23,41  €
Spread / Highest target 41,0%
Spread / Average Target 26,6%
Spread / Lowest Target 6,79%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE1.56%3 834
LONZA GROUP15.66%31 039
IQVIA HOLDINGS INC.2.31%30 480
SEATTLE GENETICS, INC.1.52%19 982
CELLTRION, INC.--.--%18 525
INCYTE CORPORATION-7.36%17 097